Home › Prostate Cancer › NCT06389097
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
Single-Photon Emission Computed Tomography (SPECT) Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (SEEtoTREAT)
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: * Cohort A: Patients with advanced prostate cancer planning to undergo treatment with Radium-223 * Cohort B: Patients with advanced cancer undergoing treatment with 177Lu-DOTATATE or 177Lu-PSMA-617 \*\*Eligible patients may be planning to undergo these treatments as part of standard of care or as part of another research protocol * Age \> 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologic confirmation of malignancy Exclusion Criteria: * Patient is participating in another research protocol that does not allow participation in this imaging protocol or that has schedule of procedures that would not be compatible with this protocol. * Patient unable to tolerate SPECT scan time, scan frequency, or position.
About the study
The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (\~20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.
What is being tested
- Radium-223 (radiation)
- 177Lu-DOTATATE (radiation)
- 177Lu-PSMA-617 (radiation)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Participants: 80 · Started: Feb 3, 2025
Contact the study team
- Ana Kiess · Phone: 443-287-7528
- Ryan Manuel · Phone: 410-955-4261
Official record on ClinicalTrials.gov — NCT06389097
Locations in the U.S.
| Maryland | Johns Hopkins University, Baltimore |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.